Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

25.38 +0.06 (+0.24%)
Official Closing Price Updated: 5:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
37 38 Next >
Pfizer Invites Public to View and Listen to Webcast of December 17 Conference Call with Analysts to Provide Full-Year 2025 Financial Guidance
From Pfizer Inc.
Via Business Wire
Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium
From Arvinas Inc.
Via GlobeNewswire
Pfizer Showcases Scientific Leadership in Breast Cancer and Blood Disorders Across More than 100 Presentations at ASH and SABCS
From Pfizer Inc.
Via Business Wire
Advocating for Justice: Supporting Individuals in the Depo-Provera Litigation
Via Get News
Topics Lawsuit
Pfizer Announces New Chief Scientific Officer and President, Research & Development
From Pfizer Inc.
Via Business Wire
European Commission Approves Pfizer’s HYMPAVZI™ (marstacimab) for the Treatment of Adults and Adolescents with Severe Hemophilia A or B Without Inhibitors
From Pfizer Inc.
Via Business Wire
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
AWKO Files Lawsuit on Behalf of Sickle Cell Patient Against Pfizer’s Subsidiary
San Francisco, California - Trebor Hardiman, a sickle cell patient from California, has filed a lawsuit against Pfizer’s wholly owned subsidiary Global Blood 
Via Law Firm Newswire
Topics Lawsuit
Pfizer Reports Strong Third-Quarter 2024 Results And Raises 2024 Guidance
From Pfizer Inc.
Via Business Wire
Advisory Committee on Immunization Practices Recommends PREVNAR 20® (20-Valent Pneumococcal Conjugate Vaccine) for Adults Aged 50 and Older
From Pfizer Inc.
Via Business Wire
U.S. FDA Approves Pfizer’s RSV Vaccine ABRYSVO® for Adults Aged 18 to 59 at Increased Risk for Disease
From Pfizer Inc.
Via Business Wire
Tim Buckley Elected to Pfizer’s Board of Directors
From Pfizer Inc.
Via Business Wire
U.S. FDA Approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors
From Pfizer Inc.
Via Business Wire
Pfizer’s TALZENNA® in Combination with XTANDI® Prolongs Overall Survival in Phase 3 TALAPRO-2 Trial
From Pfizer Inc.
Via Business Wire
Pfizer Declares Fourth-Quarter 2024 Dividend
From Pfizer Inc.
Via Business Wire
These 3 Stocks Just Spiked—Buy the Rally or Sell the News?
Investors received news about three stocks that moved each stock higher, but now investors have to decide whether to buy the rally or take some profits 
Via MarketBeat
Pfizer to Showcase Scientific Advancements in Respiratory and Other Infectious Diseases at IDWeek 2024
From Pfizer Inc.
Via Business Wire
Fifth Avenue Animate Launches New Website to Highlight Expertise in SaaS and Finance Video Marketing
Mississauga, Ontario () October 8, 2024 -- Agency continues to deliver high-impact animated content, helping businesses explain complex concepts and drive customer engagement. 
Via Prodigy
4 Reasons Pfizer Could Be a Value Play You Can't Miss
Pfizer Inc. (NYSE: PFE) hit its peak during the COVID-19 pandemic when its vaccines developed with BioNTech SE (NASDAQ: BNTX) sent shares surging up to $61.71 
Via MarketBeat
3 Stocks Set to Benefit from Cooling Inflation Trends
Three stocks stand out in the way they can outperform the rest of the industry despite a slowing inflation rate in the economy, with high income 
Via MarketBeat
Topics Economy
Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition
Via Investor Brand Network
Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition
EQNX::TICKER_START (NYSE:ANVS),(NYSE:LLY),(NYSE:PFE),(NYSE:NVO),(NASDAQ:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA® (voxelotor) From Worldwide Markets
From Pfizer Inc.
Via Business Wire
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NYSE:MRK),(NYSE:PFE),(NASDAQ:GLMD) EQNX::TICKER_END 
Via FinancialNewsMedia
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
From FN Media Group LLC
Via GlobeNewswire
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
From Pfizer Inc.
Via Business Wire
Pfizer Invites Public to View and Listen to Webcast of October 29 Conference Call with Analysts
From Pfizer Inc.
Via Business Wire
Kalm Therapeutics Hires Former GSK Director Dr. Tomoko Maeda-Chubachi as Chief Medical Officer
Huntsville, Alabama--(Newsfile Corp. - September 16, 2024) - Kalm Therapeutics (Kalm Tx) is pleased to announce the appointment of Dr.... 
Via Newsfile
Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia
From Pfizer Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
37 38 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.